Открытое несравнительное исследование препарата импазы для лечения эректильной дисфункции
- Авторы: Мазо ЕБ1, Гамидов СИ1, Овчинников РИ1
-
Учреждения:
- Урологическая клиника РГМУ
- Выпуск: № 3 (2003)
- Страницы: 28-31
- Раздел: Статьи
- URL: https://journals.eco-vector.com/1728-2985/article/view/274926
- ID: 274926
Цитировать
Полный текст
Аннотация
Clinical efficacy and safety of the drug impase in erectile dysfunction (ED) were studied in 30 patients with ED of various genesis (mean age 52.0914.75 years). IIED questionnairing was employed, combined andrological examination and standard laboratory investigations. Impase was taken 1 tablet a day each other day for 12 weeks irrespective of the intercourse. The number of attempted intercourses was at least 4 times a month. The treatment efficacy was assessed by changes of IIED parameters, subjective and objective effects. ED was
psychogenic in 5 (16.7%) patients, organic in 25 (83.3%) patients. Blood hormones were normal for age in all the patients. According to IIED, "erectile function" mean score after 12 week treatment rose from 18.89±5.25 to 22.50±4.86. In 11 (36.7%), 4 (13.3%), 5 (16.7%) patients the response was rated as excellent, good and satisfactory, respectively. No response was stated in 10 (33.3%) patients. Side effects were absent. Tolerance and safety were excellent. Thus, efficacy of impase therapy varied from 60 to 66.7% depending on ED etiology and pathogenesis. Cost-efficacy, absence of side effects, possible parallel therapy of concurrent diseases, course administration are advantages of the treatment.
psychogenic in 5 (16.7%) patients, organic in 25 (83.3%) patients. Blood hormones were normal for age in all the patients. According to IIED, "erectile function" mean score after 12 week treatment rose from 18.89±5.25 to 22.50±4.86. In 11 (36.7%), 4 (13.3%), 5 (16.7%) patients the response was rated as excellent, good and satisfactory, respectively. No response was stated in 10 (33.3%) patients. Side effects were absent. Tolerance and safety were excellent. Thus, efficacy of impase therapy varied from 60 to 66.7% depending on ED etiology and pathogenesis. Cost-efficacy, absence of side effects, possible parallel therapy of concurrent diseases, course administration are advantages of the treatment.
Об авторах
Е Б Мазо
Урологическая клиника РГМУМосква; Урологическая клиника РГМУ
С И Гамидов
Урологическая клиника РГМУМосква; Урологическая клиника РГМУ
Р И Овчинников
Урологическая клиника РГМУМосква; Урологическая клиника РГМУ
Список литературы
- Feldman H. A., Goldstein I., Hatzkhristou D. G. et al. J. Urol. (Baltimore) 1994; 151: 54-61.
- Goldstein I., Lite T. F., Padma-Nathan H. et al. N. Engl. J. Med. L998; 338: 1397-1404.
- Morales A., Gingell C., Collins M., et al. Int. J. lmpot. Res. 1998; 10: 69-74.
- Padma-Nathan H., Steers W. D., Wicker P. A. Int. J. Clin. Pract. 1998; 52: 375-379.
- Wespes E., Amar E. et al. Eur. Urol. 2002; 41: 1-5.
- Боровская Т. Г., Лоскутова О. П., Эпштейн О. И., Зак М. С. Бюл. экспер. биол. 2001; Прил. 3: 52-53.
- Smolenov I. V., Dygai A. M., Epstein О. I. et al. Pharmacologist 2002; 44 (2, suppl. 1): A167.
- Петров В. И., Дыгай А. М., Мартюшев А. В. и др. В кн.: Материалы Медико-фармацевтического форума. М.; 2002. 86-87.